BTIG Reiterates Buy on Nurix Therapeutics, Maintains $32 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 85.8%

Neg 0% Neu 85.8% Pos 0%

BTIG analyst Jeet Mukherjee reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $32 price target.

Comments

No comments yet. Be the first!